This site is intended for health professionals only
Tuesday 18 December 2018
Share |

Latest News

European Commission approval for self-administration of Xolair® across all indications

Monday 17th December 2018
Novartis has announced that the European Commission (EC) has approved Xolair® (omalizumab) prefilled syringe (PFS) for self-administration, allowing patients with severe allergic asthma (SAA) and chronic spontaneous urticaria (CSU) to administer their own treatment.
With this approval, Xolair is the first and only biologic to offer the option of self-administration for SAA and CSU.
Tue, 27 Nov 2018
The Health Foundation report found that 10,000 deaths could be prevented each year with better diagnosis
Tue, 27 Nov 2018
Findings suggest the method's potential for dramatically reducing gadolinium dose without sacrificing diagnostic quality
Tue, 27 Nov 2018
Researchers and cybersecurity experts have begun to examine ways to mitigate the risk of cyberattacks in medical imaging before they become a real danger
Tue, 27 Nov 2018
If approved, Poteligeo will be the first biologic agent targeting CCR4 to be available for patients in Europe
Thu, 22 Nov 2018
MRI exams of the brain using diffusion tensor imaging are a promising option for analysis of dementia risk
Thu, 22 Nov 2018
The amount of money medicines cost the NHS has more than doubled in less than 10 years, official figures have revealed
Thu, 22 Nov 2018
AR101 slowly builds up tolerance to peanut allergy, study finds